Stock listing
NYSE American:IBO Impact BioMedical, Inc. Stock
Home listing (NYSE American) of Impact BioMedical, Inc.
Follow Impact BioMedical, Inc. into a list and get an email when it puts out news.
Share price · AMEX:IBO
$6.17 USD +1.26 (+25.7%)
Close on Nov 17, 2026
- Day range
- $5.13 – $6.45 USDNov 17, 2026
- Volume
- 25,481 sharesNov 17, 2026
- Market cap
- $53.31M USDAt the close on Nov 17, 2026 · price × 8.64M shares outstanding
- 52-week range
- $2.43 – $10.44 USDLowest and highest trades, Nov 18, 2025 – Nov 17, 2026
- Traded on an average day
- $47,062 USDMedian day 8,189 shares · last 3 months, Aug 17, 2026 – Nov 17, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:IBO · Home | $6.17 USD | +1.26 (+25.7%) | 25,481 | $5.185 | $6.45 | $5.131 | $4.91 | Close on Nov 17, 2026 |
Daily closes
Last 3 months, Aug 17, 2026 – Nov 17, 2026 · AMEX:IBO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $6.17 | +1.26 | +25.7% | $5.185 | $6.45 | $5.131 | 25,481 | |
| $4.91 | -0.23 | -4.5% | $5.13 | $5.15 | $4.90 | 12,992 | |
| $5.14 | +0.37 | +7.8% | $4.90 | $5.177 | $4.90 | 9,860 | |
| $4.77 | +0.47 | +10.9% | $4.59 | $5.035 | $4.59 | 7,239 | |
| $4.30 | -0.32 | -6.9% | $4.51 | $4.51 | $4.30 | 1,696 | |
| $4.62 | +0.29 | +6.7% | $4.30 | $4.62 | $4.30 | 10,216 | |
| $4.33 | +0.23 | +5.6% | $4.03 | $4.70 | $4.01 | 4,448 | |
| $4.10 | -0.30 | -6.8% | $4.39 | $4.39 | $4.05 | 3,255 | |
| $4.40 | +0.30 | +7.3% | $4.10 | $4.48 | $4.00 | 14,477 | |
| $4.10 | +0.08 | +2.0% | $4.18 | $4.525 | $3.88 | 33,691 | |
| $4.02 | +0.01 | +0.2% | $4.43 | $4.51 | $4.00 | 16,743 | |
| $4.01 | +0.21 | +5.5% | $3.80 | $4.48 | $3.80 | 20,639 | |
| $3.80 | -0.07 | -1.8% | $3.52 | $4.10 | $3.52 | 15,292 | |
| $3.87 | -0.12 | -3.0% | $4.25 | $4.25 | $3.71 | 23,862 | |
| $3.99 | +0.44 | +12.4% | $3.40 | $4.38 | $3.40 | 39,888 | |
| $3.55 | -0.18 | -4.8% | $3.78 | $4.11 | $3.55 | 12,269 | |
| $3.73 | +0.13 | +3.6% | $3.74 | $3.88 | $3.10 | 12,613 | |
| $3.60 | -0.20 | -5.3% | $3.69 | $4.02 | $3.54 | 11,828 | |
| $3.80 | -0.22 | -5.5% | $3.82 | $4.23 | $3.60 | 21,552 | |
| $4.02 | +0.752 | +23.0% | $3.60 | $4.32 | $3.60 | 27,680 | |
| $3.268 | +0.208 | +6.8% | $2.78 | $3.42 | $2.674 | 12,335 | |
| $3.06 | +0.38 | +14.2% | $2.66 | $3.75 | $2.66 | 47,951 | |
| $2.68 | -0.478 | -15.1% | $3.21 | $3.21 | $2.43 | 10,214 | |
| $3.158 | -0.245 | -7.2% | $3.17 | $4.08 | $2.62 | 29,041 | |
| $3.403 | -0.577 | -14.5% | $3.59 | $3.85 | $3.25 | 3,967 | |
| $3.98 | -0.05 | -1.2% | $4.11 | $4.11 | $3.84 | 9,476 | |
| $4.03 | -0.22 | -5.2% | $4.25 | $4.46 | $4.00 | 7,387 | |
| $4.25 | +0.14 | +3.4% | $4.13 | $4.39 | $4.13 | 4,028 | |
| $4.11 | -0.37 | -8.3% | $4.32 | $4.41 | $4.06 | 17,560 | |
| $4.48 | -0.20 | -4.3% | $4.57 | $4.59 | $4.36 | 10,739 | |
| $4.68 | -0.16 | -3.3% | $5.00 | $5.05 | $4.43 | 21,172 | |
| $4.84 | -0.48 | -9.0% | $5.16 | $5.42 | $4.84 | 17,338 | |
| $5.32 | -0.11 | -2.0% | $5.54 | $5.54 | $5.265 | 11,554 | |
| $5.43 | -0.17 | -3.0% | $5.88 | $5.88 | $5.43 | 8,991 | |
| $5.60 | 0.00 | 0.0% | $5.48 | $5.75 | $5.48 | 3,926 | |
| $5.60 | -0.01 | -0.2% | $5.50 | $6.17 | $5.43 | 9,044 | |
| $5.61 | -0.08 | -1.4% | $5.69 | $6.023 | $5.59 | 9,265 | |
| $5.69 | +0.04 | +0.7% | $5.80 | $6.50 | $5.58 | 20,645 | |
| $5.65 | -0.98 | -14.8% | $6.86 | $6.86 | $5.51 | 23,370 | |
| $6.63 | -0.008 | -0.1% | $6.46 | $7.11 | $5.62 | 40,516 | |
| $6.638 | -0.353 | -5.1% | $6.98 | $6.98 | $6.638 | 972 | |
| $6.991 | -0.432 | -5.8% | $7.423 | $7.509 | $6.921 | 572 | |
| $7.423 | +0.233 | +3.2% | $7.19 | $7.423 | $6.921 | 613 | |
| $7.19 | +0.924 | +14.7% | $6.565 | $7.675 | $6.565 | 1,604 | |
| $6.266 | -0.39 | -5.9% | $6.795 | $6.882 | $6.266 | 1,034 | |
| $6.656 | +0.565 | +9.3% | $6.04 | $6.906 | $6.021 | 764 | |
| $6.09 | +0.30 | +5.2% | $5.688 | $6.516 | $5.688 | 710 | |
| $5.79 | +0.241 | +4.3% | $5.621 | $6.165 | $5.621 | 1,950 | |
| $5.549 | -0.663 | -10.7% | $5.977 | $6.395 | $5.457 | 1,711 | |
| $6.212 | -0.08 | -1.3% | $6.405 | $6.417 | $6.061 | 309 | |
| $6.291 | -0.504 | -7.4% | $6.417 | $6.715 | $6.291 | 948 | |
| $6.795 | +0.755 | +12.5% | $6.04 | $8.053 | $5.914 | 25,955 | |
| $6.04 | -0.125 | -2.0% | $6.04 | $6.152 | $5.915 | 518 | |
| $6.165 | +0.403 | +7.0% | $5.944 | $6.165 | $5.788 | 283 | |
| $5.762 | -0.039 | -0.7% | $6.077 | $6.165 | $5.732 | 168 | |
| $5.801 | +0.218 | +3.9% | $5.549 | $5.92 | $5.549 | 53 | |
| $5.583 | +0.034 | +0.6% | $5.583 | $5.788 | $5.562 | 42 | |
| $5.549 | +0.011 | +0.2% | $5.536 | $5.794 | $5.536 | 322 | |
| $5.538 | -0.252 | -4.4% | $5.623 | $6.136 | $5.536 | 82 | |
| $5.79 | +0.091 | +1.6% | $5.964 | $6.152 | $5.536 | 338 | |
| $5.699 | -0.341 | -5.6% | $5.717 | $6.01 | $5.675 | 89 | |
| $6.04 | +0.387 | +6.9% | $5.515 | $6.04 | $5.515 | 143 | |
| $5.652 | +0.202 | +3.7% | $5.413 | $5.772 | $5.413 | 153 | |
| $5.451 | -0.463 | -7.8% | $5.735 | $5.824 | $5.451 | 197 | |
| $5.914 | -0.093 | -1.6% | $5.781 | $6.005 | $5.775 | 167 | |
| $6.007 | +0.228 | +4.0% | $5.536 | $6.027 | $5.536 | 343 |
Splits
1 split · AMEX:IBO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12.62 | Consolidation |
- Ticker
- NYSE American:IBO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news
Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination
Nov 2, 2026
Closed $4.02 (+0.2%) on Nov 3, 2026
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
Sep 16, 2026
Closed $6.27 (-5.9%) on Sep 16, 2026
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley's Ltd.)
Sep 14, 2026
Closed $6.09 (+5.2%) on Sep 14, 2026
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
Apr 3, 2026
Closed $8.05 (+8.4%) on Apr 6, 2026
Impact BioMedical, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 5 in the last 12 months · 9 in all · newest Nov 3, 2026 · oldest 2024
- Decks
- 3 decks · latest January 2025
Where Impact BioMedical, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:IBO · Home listing · This page | NYSE American | United States | USD |
| BOATS:IBO | BOATS | United States | USD |
Valuation
EV/sales 1,402× against a median of 23.6×: the highest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 17, 2026
- Enterprise value
- $53.29M USD
- P/E
- 33.0×
- EV/sales
- 1,402×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.3×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.06
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| EyeGene, Inc. · KRX:185490 | US$55.23M | US$26.50M | n/a | 8.0× | n/a | 1.5× | −391.5% | 0.0× | n/a |
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.54M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Anavex Life Sciences Corp. · NASDAQ:AVXL | US$54.83M | −US$63.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 2.39 |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$54.64M | US$29.75M | 23.6× | 0.9× | −132.6% | 0.0× | 0.71 |
Team and board
Officers
| Officer | Role |
|---|---|
| Frank D. Heuszel | Chief Executive Officer |
| Todd Macko | Chief Financial Officer |
| Mark Suseck | Chief Operating Officer |
Board
| Director | Role |
|---|---|
| Frank D. Heuszel | Chief Executive Officer |
| Ambrose Chan Heng Fai | |
| Castel Hibbert | |
| Chris Zimmerman | |
| David Keene | |
| Elise Brownell | |
| Jason Grady | |
| Melissa Sims |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 | +12.7% |
| Q2 2026 | Aug 7, 2026 | −3.4% |
| Q3 2025 | Nov 7, 2025 | +4.8% |
| Q2 2025 | Aug 14, 2025 | +5.0% |
| Q1 2025 | May 14, 2025 | −6.4% |
| Q4 2024 | Mar 28, 2025 | −61.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2025) | Investor deck | 19 slides | January 2025 |
| Investor Presentation (November 2024) | Investor deck | 10 slides | Nov 4, 2024 |
| Investor Presentation (August 2024) | Investor deck | 16 slides | August 2024 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.0K | 1.62M | 1.03M | 50.0K | 50.0K | 0 | |||
| Cost of revenue | 424.0K | 1.12M | 1.12M | 1.11M | 1.11M | ||||
| Gross profit | -392.0K | 1.62M | -1.12M | 50.0K | 50.0K | ||||
| Research and development | 340.0K | 278.0K | 1.69M | 1.23M | 1.23M | 513.7K | 442.3K | ||
| Selling, general and administrative | 873.0K | 718.0K | 315.0K | 325.0K | 1.05M | 383.4K | 237.7K | 68.8K | 176.2K |
| Operating income | -4.28M | -28.8M | -4.03M | -3.40M | -3.40M | -896.7K | -680.0K | -33.9K | 64.0K |
| Depreciation and amortization | 1.15M | 1.12M | 1.12M | 1.11M | 1.11M | 1.14M | 255 | 171.9K | 161.1K |
| EBITDA | -3.14M | -27.6M | -2.91M | -2.29M | -2.29M | 244.3K | -679.8K | 138.0K | 225.1K |
| Interest expense | 793.0K | 1.06M | 444.0K | 462.0K | 300.0K | ||||
| Income before tax | -14.4M | -24.7M | -4.41M | -7.88M | -7.88M | -896.7K | -849.2K | -98.1K | -408.3K |
| Income tax | -2.58M | 33.0K | -621.0K | -621.0K | -82.0K | 59.1K | |||
| Net income | -11.8M | -24.7M | -4.34M | -7.25M | -7.05M | -597.3K | -590.1K | -98.1K | -408.3K |
| Earnings per share, basic | -0.38 | -2.30 | -0.07 | -0.10 | -7.74 | -0.66 | -0.05 | -0.01 | -0.04 |
| Earnings per share, diluted | -0.38 | -2.30 | -0.07 | -0.10 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.00K | 2.00M | 1.00K | 2.00K | 46.0K | 72.3K | 97.7K | 204.9K | 51.9K | 387.8K |
| Short-term investments | 2.00M | |||||||||
| Receivables | 5.00K | 201.0K | 0 | 16.0K | 197.0K | 14.1K | 35.2K | 4.38K | 28.6K | 850 |
| Inventory | 63.0K | -265 | ||||||||
| Current assets | 411.0K | 2.45M | 332.0K | 122.0K | 287.0K | 107.3K | 115.3K | 217.2K | 320.7K | 405.6K |
| Property, plant and equipment | 0 | 17.0K | 287.0K | 276.0K | ||||||
| Goodwill | 25.1M | 25.1M | 25.1M | 25.1M | 25.1M | |||||
| Total assets | 17.4M | 20.3M | 44.6M | 46.5M | 56.4M | 48.1M | 116.6K | 217.2K | 320.7K | 405.6K |
| Accounts payable | 347.0K | 314.0K | 832.0K | 539.0K | 115.0K | 9.27K | ||||
| Current liabilities | 1.16M | 9.79M | 13.1M | 10.6M | 12.6M | 1.07M | 21.7K | 20.1K | 25.4K | 5.60K |
| Total debt | 8.88M | 12.1M | 9.99M | 12.5M | 1.06M | |||||
| Total liabilities | 1.85M | 13.1M | 16.4M | 13.8M | 16.5M | 6.32M | 21.7K | 20.1K | 25.4K | 5.60K |
| Shareholders' equity | 12.3M | 4.26M | 25.2M | 29.6M | 36.6M | 37.9M | 94.9K | 197.1K | 295.2K | 400.0K |
| Shares outstanding | 8.29M | 11.5M | 10.0M | 70.5M | 911.6K | 911.6K | 11.8M | 9.81M | 10.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.89M | -2.85M | -2.85M | -2.24M | -2.24M | -898.5K | -122.0K | -72.0K | -320.3K |
| Capital spending | 0 | 0 | -18.0K | -276.0K | -276.0K | -3 | -1.53K | 0 | 0 |
| Free cash flow | -1.89M | -5.64M | -2.87M | -2.52M | -2.52M | -898.5K | -123.5K | -72.0K | -320.3K |
| Cash from investing | 3.00K | 2.00K | -15.0K | -349.0K | -349.0K | -632.1K | -26.5K | 225.0K | -225.0K |
| Cash from financing | -109.0K | 4.85M | 2.87M | 2.55M | 2.55M | 1.49M | 16.1K | 209.5K | |
| Dividends paid | -410.0K | -410.0K | |||||||
| Share buybacks | 3.73M | -46.5K | -46.5K | ||||||
| Change in cash | -2.00M | 2.00M | -1.00K | -44.0K | -44.0K | 72.3K | -132.4K | 153.0K | -335.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Acquisition or disposal | SEC |
| 25-NSE | Nov 18, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
All 159 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 3, 2026 | Current report | SEC |
| 425 | Nov 3, 2026 | Other filings | SEC |
| DEFM14A | Oct 26, 2026 | Meeting notice | SEC |
| 8-K · Current report | Oct 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 24, 2026 | Insider trade | SEC |
| 425 | Sep 16, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
| 425 | Sep 14, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Apr 29, 2026 | Other filings | SEC |
| S-8 POS | Apr 22, 2026 | Offer document | SEC |
| S-8 POS | Apr 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2026 | Insider trade | SEC |
| 10-K · Annual report | Mar 11, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| DEF 14C | Dec 30, 2025 | Meeting notice | SEC |
| PRE 14C | Dec 11, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Oct 27, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Sep 22, 2025 | Meeting notice | SEC |
| DEF 14C | Sep 9, 2025 | Meeting notice | SEC |
| PRE 14C | Aug 26, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| DEF 14C | Aug 5, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 28, 2025 | Material contract | SEC |
| PRE 14C | Jul 16, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 23, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 3, 2025 | Material contract | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2025 | Material contract | SEC |
| 4 · Change in ownership | Mar 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2025 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Mar 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 29, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jan 24, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 10, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| 8-K · Current report | Oct 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 3/A · Initial statement of ownership, amended | Sep 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2024 | Material contract | SEC |
| 3 · Initial statement of ownership | Sep 17, 2024 | Insider trade | SEC |
| 424B4 · Prospectus | Sep 17, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 16, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 5, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 5, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 27, 2024 | Offer document | SEC |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Aug 23, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 20, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | Aug 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 12, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 9, 2024 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Aug 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 8, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Aug 8, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 11, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 7, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| S-1/A · Registration statement, amended | Feb 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 20, 2024 | Annual report | SEC |
| 8-K · Current report | Jan 22, 2024 | Material contract | SEC |
| S-1/A · Registration statement, amended | Nov 21, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2023 | Material contract | SEC |
| S-1/A · Registration statement, amended | Nov 1, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 25, 2023 | Other filings | SEC |
| S-1 · Registration statement | Oct 17, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 5, 2023 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 7, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 2, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 1, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 24, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 24, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 13, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 30, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 30, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 27, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 21, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 21, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 9, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 2, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 2, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 25, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 15, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 31, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 31, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 20, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 9, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 9, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 3, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 7, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 7, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 31, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 24, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 24, 2022 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 11, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 2, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 2, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 21, 2022 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jul 11, 2022 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jun 24, 2022 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 24, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 26, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2021 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 29, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 24, 2021 | Other filings | SEC |
| S-1 · Registration statement | Feb 12, 2021 | Offer document | SEC |
Cap table
Built by 6ix from Impact BioMedical, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 8,640,000
- Fully diluted
- 8,640,000
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 8,640,000 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 8,640,000 |
| Sep 14, 2026 | |
| Sep 11, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Heng Fai Ambrose Chan Other companies: HWH International Inc. (Chief Executive Officer, Director · Since at least Jan 9, 2024); Alset Inc. (Chief Executive Officer, Director · Since at least Nov 23, 2020); DSS, Inc. (Director · Since at least Jan 12, 2017); Value Exchange International, Inc. (Director · Oct 3, 2022 – Mar 28, 2025 · Past); Sharing Services Global Corp. (Director · Apr 30, 2020 – Mar 31, 2025 · Past); OptimumBank Holdings, Inc. (Director · Jun 26, 2018 – Jul 23, 2021 · Past); Chiron Real Estate Inc. (Director · Apr 14, 2014 – Apr 14, 2014 · Past) | Director · Since at least Mar 31, 2025 |
| Ambrose Chan Heng Fai Other companies: DSS, Inc. (Executive Chairman, Director · Since at least Nov 5, 2026) | Director · Since at least Nov 5, 2026 |
| Jason T. Grady Other companies: DSS, Inc. (Interim CEO · Since at least Jul 11, 2019) | Director · Since at least Sep 16, 2024 |
| Todd D. Macko Other companies: DSS, Inc. (CFO · Since at least Oct 28, 2020) | Chief Financial Officer · Since at least Sep 16, 2024 |
| Castel Hibbert | Director · Since at least Oct 7, 2026 |
| Christian Thomas Zimmerman | Director · Since at least Sep 16, 2024 |
| Chris Zimmerman | Director · Since at least Nov 4, 2026 |
| David Keene | Director · Since at least Sep 16, 2024 |
| Elise Brownell | Director · Since at least Sep 16, 2024 |
| Frank D. Heuszel | Chief Executive Officer · Since at least Nov 3, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Mark Suseck | Chief Operating Officer · Since at least Sep 16, 2024 |
| Melissa Sims | Director · Since at least Sep 16, 2024 |
Log in to ask 6ix AI your own questions about Impact BioMedical, Inc.